BridgeBio Pharma Inc (NASDAQ: BBIO) stock dropped after Pfizer withdrew a patent in the European Union. Despite hitting a three-month low, BBIO shares are up 5.2% at $71.57. Technical support, including the 100-day moving average, shows strong stock performance.

Analyst Rocky White notes BBIO is close to its 100-day moving average’s 20-day ATR, signaling potential growth. Short interest is at 11% of available float, pointing to potential buying power. Options activity at ISE, CBOE, and PHLX suggests bearish sentiment.

BBIO stock shows resilience after recent setbacks, with potential for upward movement in the coming month.

Read more at Yahoo Finance: Buy the Dip on This Biotech Stock After Recent Fall